LMR Partners’s Edgewise Therapeutics EWTX Stock Holding History

LMR Partners’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$813K	Hold	20,000	–	–	﹤0.01%	1098
2026 Q1	$630K	Hold	20,000	–	–	﹤0.01%	1060
2025 Q4	$496K	Buy	+20,000	New	+$401K	﹤0.01%	1126

Other funds holding EWTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LMR Partners's EWTX Position: Q2 2026 in Review

LMR Partners held its Edgewise Therapeutics (EWTX) position steady in Q2 2026 at 20,000 shares worth $813K. The position accounts for ﹤0.01% of the portfolio, ranked #1098.

LMR Partners first reported a position in EWTX in Q4 2025 and has held it in 3 quarters since. 227 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

LMR Partners held 20,000 shares of Edgewise Therapeutics worth $813K as of Q2 2026.
LMR Partners left its Edgewise Therapeutics share count unchanged in Q2 2026.
Edgewise Therapeutics made up ﹤0.01% of LMR Partners's portfolio in Q2 2026, its #1098 holding.
LMR Partners first reported a position in Edgewise Therapeutics in Q4 2025 and has held it in 3 quarters since.
227 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.